• Markets
  • icon
  • Companies
PAA · ASX

Pharmaust Limited (ASX:PAA)

AU$0.21

 0.0 (0.0%)
ASX:Live
23/07/2024 04:10:02 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

PAA Overview

PAA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About PAA

Telephone

Address

Description

PharmAust Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. It operates under the Corporate and Research, and Pharmaceutical-Epichem segments. The Corporate and Research segment includes corporate overhead expenses. The Pharmaceutical-Epichem segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company was founded on December 2003 and is headquartered in Claremont, Australia.

PAA Price Chart

Key Stats

Market Cap

AU$95.68M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.07 - 0.54

Trade Value (12mth)

AU$49,241.00

1 week

-6.67%

1 month

2.44%

YTD

90.91%

1 year

162.5%

All time high

4.74

Key Fundamentals

EPS 3 yr Growth

321.700%

EBITDA Margin

-116.70%

Operating Cashflow

-$2m

Free Cash Flow Return

-22.90%

ROIC

-90.90%

Interest Coverage

-40.30

Quick Ratio

2.20

Other Data

Shares on Issue (Fully Dilluted)

354m

HALO Sector

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PAA Announcements

Latest Announcements

Date Announcements

15 July 24

Monepantel Selected for Entry into HEALEY ALS Platform Trial

×

Monepantel Selected for Entry into HEALEY ALS Platform Trial

15 July 24

Investor Update - HEALEY ALS Platform Trial Selection

×

Investor Update - HEALEY ALS Platform Trial Selection

08 July 24

Investor Briefings & Webinar Notice

×

Investor Briefings & Webinar Notice

01 July 24

PharmAust Granted SME Status by European Medicines Agency

×

PharmAust Granted SME Status by European Medicines Agency

28 June 24

Share Purchase Plan Cleansing Notice

×

Share Purchase Plan Cleansing Notice

28 June 24

Share Purchase Plan Offer Booklet

×

Share Purchase Plan Offer Booklet

28 June 24

Application for quotation of securities - PAA

×

Application for quotation of securities - PAA

28 June 24

Application for quotation of securities - PAA

×

Application for quotation of securities - PAA

28 June 24

Notification regarding unquoted securities - PAA

×

Notification regarding unquoted securities - PAA

28 June 24

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

27 June 24

Application for quotation of securities - PAA

×

Application for quotation of securities - PAA

21 June 24

PharmAust raises $10 million via Placement and announces SPP

×

PharmAust raises $10 million via Placement and announces SPP

21 June 24

Proposed issue of securities - PAA

×

Proposed issue of securities - PAA

21 June 24

PharmAust Presentation

×

PharmAust Presentation

19 June 24

Trading Halt

×

Trading Halt

19 June 24

Initial Director's Interest Notice - K.MacFarlane

×

Initial Director's Interest Notice - K.MacFarlane

18 June 24

PharmAust's Phase 1 Study Data Presented at Major Conference

×

PharmAust's Phase 1 Study Data Presented at Major Conference

17 June 24

Appointment of Non-Executive Director

×

Appointment of Non-Executive Director

05 June 24

OLE Study update reveals impressive Survival Data

×

OLE Study update reveals impressive Survival Data

04 June 24

Final Director's Interest Notice - J.Clark

×

Final Director's Interest Notice - J.Clark

04 June 24

Initial Director's Interest Notice - M.Thurn

×

Initial Director's Interest Notice - M.Thurn

31 May 24

Executive team strengthened, appointment of MD/CEO & new CSO

×

Executive team strengthened, appointment of MD/CEO & new CSO

28 May 24

Change of Registered Office and Principal Place of Business

×

Change of Registered Office and Principal Place of Business

24 May 24

Appointment of Company Secretary

×

Appointment of Company Secretary

17 May 24

PharmAust appoints Sergio Duchini as Non-Executive Chairman

×

PharmAust appoints Sergio Duchini as Non-Executive Chairman

PAA Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.01 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.01 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.7 -28.6 -259.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.2 -67.8 -17.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -3.6 -6.2 -6.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.02 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.0 -17.5 -84.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 316 317 321 Lock Lock Lock
Basic m Lock Lock Lock Lock 316 317 321 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 2 3 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.0 58.0 -16.5 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 2 3 3 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -82.0 71.0 -315.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -36.0 -6.6 -32.9 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 136 107 133 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 -2 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.4 2.3 -35.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -116.4 -72.0 -116.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -3 -3 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.5 1.5 -31.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -130.3 -81.3 -128.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -1 -2 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -1 -2 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.8 -27.7 -263.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -62.5 -50.5 -220.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.0 -32.3 -16.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.5 -0.4 -0.6 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 3 2 3 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 11 10 6 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -1 -2 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 9 8 4 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 9 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.8 -11.3 -46.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -12.2 -16.9 -101.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.1 -21.8 -159.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -27.7 -28.4 -51.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -13.6 -18.1 -90.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -9.5 -14.1 -22.9 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -31.5 -27.5 -40.3 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.7 0.4 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -19.7 -13.2 -42.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 4.8 3.2 2.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.7 2.3 2.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 69.4 64.9 89.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -102.9 -114.3 -116.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 7.5 14.5 13.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 3.1 3.5 7.2 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.6 1.3 1.7 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 26.1 17.9 32.8 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.5 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.5 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -62.5 -50.5 -220.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -12.2 -16.9 -101.3 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -12.2 -16.9 -101.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.3 1.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.1 -21.8 -159.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -15.1 -21.8 -159.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 116.9 103.8 50.7 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 48.8 25.1 27.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 165.7 129.0 77.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 66.5 58.3 103.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 99.2 70.7 -25.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PAA Shortsell

Frequently Asked Questions

The current share price of Pharmaust Limited (PAA:ASX) is AU$0.21.
The 52-week high share price for Pharmaust Limited (PAA:ASX) is AU$0.54.
The 52-week low share price for Pharmaust Limited (PAA:ASX)? is AU$0.07.
Pharmaust Limited (PAA:ASX) does not pay a dividend.
Pharmaust Limited (PAA:ASX) does not pay a dividend.
Pharmaust Limited (PAA:ASX) has a franking level of 0.0%.
Pharmaust Limited (PAA:ASX) is classified in the Healthcare.
The current P/E ratio for Pharmaust Limited (PAA:ASX) is .